^
Association details:
| Biomarker: | BCR-ABL1 fusion |
|---|---|
| Cancer: | Chronic Myeloid Leukemia |
| Drug Class: | Tyrosine kinase inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Excerpt:
A summary of recommendations is shown in Table 7...First-line management of chronic phase CML...TKI therapy should be commenced immediately after confirmation of BCR–ABL1 positivity. It is recommended to taper the hydroxyurea dose before its discontinuation.
DOI:
10.1093/annonc/mdx219
